Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women's health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: Health Care Supplies
- Symbol: NASDAQ:QDEL
- CUSIP: 74838J10
- Web: www.quidel.com
Capitalization:- Market Cap: $1.09 billion
- Outstanding Shares: 33,440,000
Average Prices:- 50 Day Moving Avg: $32.13
- 200 Day Moving Avg: $25.45
- 52 Week Range: $18.25 - $38.92
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 85.82
- P/E Growth: 5.80
Sales & Book Value:- Annual Revenue: $214.11 million
- Price / Sales: 5.09
- Book Value: $6.36 per share
- Price / Book: 5.13
Profitability:- EBIDTA: $39.38 million
- Net Margins: -0.03%
- Return on Equity: -0.03%
- Return on Assets: -0.02%
Debt:- Debt-to-Equity Ratio: 0.71%
- Current Ratio: 7.19%
- Quick Ratio: 6.46%
Misc:- Average Volume: 325,761 shs.
- Beta: 1.28
- Short Ratio: 7
Frequently Asked Questions for Quidel Corporation (NASDAQ:QDEL)
What is Quidel Corporation's stock symbol?
Quidel Corporation trades on the NASDAQ under the ticker symbol "QDEL."
How were Quidel Corporation's earnings last quarter?
Quidel Corporation (NASDAQ:QDEL) announced its quarterly earnings data on Wednesday, July, 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.18. The business earned $38.30 million during the quarter, compared to the consensus estimate of $41.91 million. Quidel Corporation had a negative net margin of 0.03% and a negative return on equity of 0.03%. The firm's revenue for the quarter was down 2.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.11) EPS. View Quidel Corporation's Earnings History.
When will Quidel Corporation make its next earnings announcement?
Where is Quidel Corporation's stock going? Where will Quidel Corporation's stock price be in 2017?
6 analysts have issued 12-month price objectives for Quidel Corporation's stock. Their forecasts range from $22.00 to $41.00. On average, they anticipate Quidel Corporation's share price to reach $31.75 in the next year. View Analyst Ratings for Quidel Corporation.
Who are some of Quidel Corporation's key competitors?
Some companies that are related to Quidel Corporation include Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), ABAXIS (ABAX), Mazor Robotics (MZOR), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), GenMark Diagnostics (GNMK), Pacific Biosciences of California (PACB), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Alliance HealthCare Services (AIQ), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Harvard Bioscience (HBIO), Fulgent Genetic (FLGT), Viveve Medical (VIVE) and IRIDEX Corporation (IRIX).
Who are Quidel Corporation's key executives?
Quidel Corporation's management team includes the folowing people:
- Kenneth F. Buechler Ph.D., Chairman of the Board
- Douglas C. Bryant, President, Chief Executive Officer, Director
- Randall J. Steward, Chief Financial Officer
- Robert Joseph Bujarski J.D., Senior Vice President - Business Development, General Counsel and Corporate Secretary
- Michael D. Abney Jr., Senior Vice President - Distribution
- Werner Kroll Ph.D, Senior Vice President,R&D
- Edward Keith Russell, Senior Vice President - Global Commercial Operations
- John D. Tamerius Ph.D., Senior Vice President - Strategic and External Affairs
- Charles P. Slacik CPA, Director
- Thomas D. Brown, Independent Director
Who owns Quidel Corporation stock?
Quidel Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.56%), Macquarie Group Ltd. (3.87%), New York State Common Retirement Fund (2.67%), Dimensional Fund Advisors LP (2.53%), Fred Alger Management Inc. (2.01%) and Gamco Investors INC. ET AL (1.89%). Company insiders that own Quidel Corporation stock include Douglas C Bryant, John Tamerius, Michael Donald Jr Abney, Randall J Steward and Robert Joseph Bujarski. View Institutional Ownership Trends for Quidel Corporation.
Who sold Quidel Corporation stock? Who is selling Quidel Corporation stock?
Quidel Corporation's stock was sold by a variety of institutional investors in the last quarter, including Investment Management of Virginia LLC, ETRADE Capital Management LLC, Trexquant Investment LP, Parametric Portfolio Associates LLC, Pitcairn Co., California State Teachers Retirement System, Alliancebernstein L.P. and Dimensional Fund Advisors LP. Company insiders that have sold Quidel Corporation stock in the last year include Douglas C Bryant, John Tamerius, Michael Donald Jr Abney, Randall J Steward and Robert Joseph Bujarski. View Insider Buying and Selling for Quidel Corporation.
Who bought Quidel Corporation stock? Who is buying Quidel Corporation stock?
Quidel Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Chicago Equity Partners LLC, Marshall Wace North America L.P., Renaissance Technologies LLC, Janus Henderson Group PLC, Acadian Asset Management LLC, Spark Investment Management LLC, Macquarie Group Ltd. and Arrowstreet Capital Limited Partnership. View Insider Buying and Selling for Quidel Corporation.
How do I buy Quidel Corporation stock?
Shares of Quidel Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quidel Corporation's stock price today?
One share of Quidel Corporation stock can currently be purchased for approximately $32.61.
MarketBeat Community Rating for Quidel Corporation (NASDAQ QDEL)MarketBeat's community ratings are surveys of what our community members think about Quidel Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Quidel Corporation (NASDAQ:QDEL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $31.75 (2.64% downside) |
Analysts' Ratings History for Quidel Corporation (NASDAQ:QDEL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/27/2017 | Raymond James Financial, Inc. | Boost Price Target | Outperform | $36.00 -> $41.00 | High |  |
| 7/27/2017 | Barclays PLC | Boost Price Target | Overweight | $36.00 -> $39.00 | High | |
| 7/18/2017 | William Blair | Upgrade | Market Perform -> Outperform | | High | |
| 7/18/2017 | Canaccord Genuity | Upgrade | Hold -> Buy | | High | |
| 2/17/2017 | CL King | Initiated Coverage | Neutral | | N/A | |
| 12/16/2016 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | $22.00 | N/A | |
| 2/18/2016 | Craig Hallum | Lower Price Target | Hold | $18.00 -> $16.00 | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for Quidel Corporation (NASDAQ:QDEL)Earnings History by Quarter for Quidel Corporation (NASDAQ QDEL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | | | | | | N/A | |
| 7/26/2017 | Q2 2017 | ($0.17) | ($0.35) | $41.91 million | $38.30 million | View | N/A | |
| 4/24/2017 | Q1 2017 | $0.15 | $0.45 | $61.85 million | $73.70 million | View | N/A | |
| 2/8/2017 | Q416 | $0.02 | $0.17 | $58.42 million | $52.80 million | View | Listen | |
| 10/26/2016 | Q316 | ($0.02) | $0.10 | $50.88 million | $49.30 million | View | Listen | |
| 7/27/2016 | Q216 | ($0.25) | ($0.11) | $37.98 million | $39.10 million | View | Listen | |
| 4/27/2016 | Q116 | ($0.07) | $0.02 | $49.21 million | $50.30 million | View | Listen | |
| 2/17/2016 | Q415 | $0.05 | $0.10 | $54.01 million | $52.40 million | View | Listen | |
| 10/28/2015 | Q315 | ($0.14) | $0.05 | $43.48 million | $46.80 million | View | Listen | |
| 7/22/2015 | Q215 | ($0.25) | ($0.14) | $34.17 million | $34.87 million | View | Listen | |
| 4/23/2015 | Q115 | $0.12 | $0.30 | $61.22 million | $61.30 million | View | Listen | |
| 2/11/2015 | Q414 | $0.10 | $0.37 | $60.61 million | $63.60 million | View | Listen | |
| 10/21/2014 | Q314 | ($0.12) | ($0.01) | $37.80 million | $40.90 million | View | Listen | |
| 7/22/2014 | Q214 | ($0.16) | ($0.10) | $31.90 million | $31.50 million | View | Listen | |
| 4/23/2014 | Q114 | $0.30 | $0.08 | $63.26 million | $46.70 million | View | Listen | |
| 2/11/2014 | Q413 | $0.09 | $0.20 | $48.67 million | $50.00 million | View | Listen | |
| 10/23/2013 | Q313 | ($0.07) | ($0.02) | $37.32 million | $33.50 million | View | Listen | |
| 7/30/2013 | Q2 2013 | ($0.11) | ($0.06) | $33.24 million | $29.71 million | View | Listen | |
| 4/23/2013 | Q1 2013 | $0.46 | $0.49 | $62.63 million | $61.99 million | View | N/A | |
| 2/12/2013 | Q4 2012 | $0.29 | $0.26 | $53.30 million | $53.93 million | View | Listen | |
| 10/23/2012 | | ($0.03) | $0.08 | | | View | N/A | |
| 7/25/2012 | | ($0.08) | $0.01 | | | View | N/A | |
| 2/29/2012 | | $0.06 | $0.15 | | | View | N/A | |
| 10/25/2011 | | ($0.06) | ($0.03) | | | View | N/A | |
| 8/2/2011 | | ($0.07) | ($0.04) | | | View | N/A | |
| 4/28/2011 | | $0.33 | $0.35 | | | View | N/A | |
| 2/24/2011 | | ($0.01) | $0.02 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Quidel Corporation (NASDAQ:QDEL)Current Year EPS Consensus Estimate: $0.28 EPS
Next Year EPS Consensus Estimate: $0.38 EPS
Dividend History for Quidel Corporation (NASDAQ:QDEL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Quidel Corporation (NASDAQ:QDEL)Insider Ownership Percentage: 22.00%
Institutional Ownership Percentage: 89.66%
Insider Trades by Quarter for Quidel Corporation (NASDAQ:QDEL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/31/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $33.83 | $1,217,880.00 | |
| 7/28/2017 | Michael Donald Jr. Abney | SVP | Sell | 1,173 | $33.83 | $39,682.59 | |
| 7/28/2017 | Randall J Steward | CFO | Sell | 94,215 | $34.09 | $3,211,789.35 | |
| 6/30/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $27.30 | $982,800.00 | |
| 5/31/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $24.98 | $899,280.00 | |
| 5/30/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $25.10 | $301,200.00 | |
| 5/26/2017 | Douglas C Bryant | CEO | Sell | 12,000 | $24.90 | $298,800.00 | |
| 5/2/2017 | Robert Joseph Bujarski | SVP | Sell | 43,225 | $24.27 | $1,049,070.75 | |
| 5/1/2017 | Robert Joseph Bujarski | SVP | Sell | 33,225 | $24.20 | $804,045.00 | |
| 4/28/2017 | Douglas C Bryant | CEO | Sell | 36,000 | $24.16 | $869,760.00 | |
| 3/31/2017 | Douglas C Bryant | CEO | Sell | 37,080 | $22.50 | $834,300.00 | |
| 2/28/2017 | Douglas C. Bryant | CEO | Sell | 106,920 | $21.39 | $2,287,018.80 | |
| 12/1/2016 | Robert Joseph Bujarski | SVP | Sell | 60,000 | $22.84 | $1,370,400.00 | |
| 11/30/2016 | Douglas C Bryant | CEO | Sell | 72,000 | $22.89 | $1,648,080.00 | |
| 11/29/2016 | Douglas C Bryant | CEO | Sell | 24,000 | $22.84 | $548,160.00 | |
| 11/28/2016 | Douglas C Bryant | CEO | Sell | 24,000 | $23.02 | $552,480.00 | |
| 11/25/2016 | John Tamerius | SVP | Sell | 8,878 | $23.50 | $208,633.00 | |
| 9/30/2016 | Douglas C Bryant | CEO | Sell | 69,168 | $21.76 | $1,505,095.68 | |
| 8/30/2016 | Douglas C Bryant | CEO | Sell | 2,832 | $22.00 | $62,304.00 | |
| 8/9/2016 | Robert Joseph Bujarski | SVP | Sell | 22,057 | $22.58 | $498,047.06 | |
| 8/1/2016 | John Tamerius | SVP | Sell | 7,000 | $23.02 | $161,140.00 | |
| 2/19/2016 | Douglas C. Bryant | CEO | Buy | 3,700 | $13.91 | $51,467.00 | |
| 12/2/2015 | John Tamerius | SVP | Sell | 21,109 | $21.95 | $463,342.55 | |
| 10/30/2015 | Douglas C Bryant | CEO | Buy | 20,000 | $19.76 | $395,200.00 | |
| 10/3/2014 | John Tamerius | SVP | Sell | 5,000 | $28.00 | $140,000.00 | |
| 9/18/2014 | John Tamerius | SVP | Sell | 10,000 | $26.50 | $265,000.00 | |
| 7/24/2014 | Douglas C Bryant | CEO | Buy | 20,000 | $24.12 | $482,400.00 | |
| 7/23/2014 | John Tamerius | SVP | Sell | 15,000 | $24.50 | $367,500.00 | |
| 6/24/2014 | John Tamerius | SVP | Sell | 5,000 | $23.06 | $115,300.00 | |
| 2/26/2014 | John Tamerius | SVP | Sell | 47,246 | $27.69 | $1,308,241.74 | |
| 2/13/2014 | Rodney Dammeyer | Director | Sell | 26,000 | $27.70 | $720,200.00 | |
| 10/29/2013 | Mark Pulido | Director | Sell | 12,750 | $25.31 | $322,702.50 | |
| 5/29/2013 | Robert Joseph Bujarski | SVP | Sell | 28,808 | $23.16 | $667,193.28 | |
| 5/17/2013 | Robert Joseph Bujarski | SVP | Sell | 27,479 | $23.12 | $635,314.48 | |
(Data available from 1/1/2013 forward)
Headline Trends for Quidel Corporation (NASDAQ:QDEL)
Latest Headlines for Quidel Corporation (NASDAQ:QDEL)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Quidel Corp. : August 15, 2017
finance.yahoo.com - August 16 at 7:03 AM |
 | Quidel Corporation (NASDAQ:QDEL) Expected to Post Quarterly Sales of $50.69 Million
www.americanbankingnews.com - August 4 at 7:08 AM |
| Zacks: Analysts Anticipate Quidel Corporation (QDEL) Will Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - August 3 at 12:32 AM |
| Quidel Corp. :QDEL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017
finance.yahoo.com - August 2 at 6:56 AM |
| Michael Donald Jr. Abney Sells 1,173 Shares of Quidel Corporation (QDEL) Stock
www.americanbankingnews.com - August 1 at 10:14 PM |
| Quidel Corporation (NASDAQ:QDEL) CFO Randall J. Steward Sells 94,215 Shares
www.americanbankingnews.com - August 1 at 10:12 PM |
| Quidel Corporation (NASDAQ:QDEL) CEO Douglas C. Bryant Sells 36,000 Shares
www.americanbankingnews.com - August 1 at 10:47 AM |
| Quidel Corporation (QDEL) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 1 at 9:23 AM |
| Quidel Corporation (QDEL) Rating Lowered to C at TheStreet
www.americanbankingnews.com - July 30 at 8:33 PM |
| Quidel Corporation (QDEL) Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - July 29 at 8:36 AM |
| Dextera Surgical (DXTR) versus Quidel Corporation (NASDAQ:QDEL) Critical Analysis
www.americanbankingnews.com - July 27 at 10:36 AM |
| Quidel Reports Second Quarter 2017 Financial Results
finance.yahoo.com - July 27 at 6:42 AM |
| Edited Transcript of QDEL earnings conference call or presentation 26-Jul-17 9:00pm GMT
finance.yahoo.com - July 27 at 6:42 AM |
| Quidel reports 2Q loss
finance.yahoo.com - July 27 at 6:42 AM |
| Quidel Corporation (NASDAQ:QDEL) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - July 26 at 9:15 PM |
| Quidel Corporation (NASDAQ:QDEL) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 23 at 12:00 AM |
| Corporate News Blog - Quidel to Acquire Alere Triage(R) Assets
finance.yahoo.com - July 20 at 7:01 AM |
 | Quidel Corp. (QDEL) Surged To A New High After Buying Assets From Alere
www.rttnews.com - July 19 at 6:08 AM |
 | Quidel (QDEL) Worth a Look: Stock Jumps 25.4% in Session
www.zacks.com - July 19 at 6:08 AM |
 | Quidel (QDEL) Updates On Acquisition Of Alere's Triage (ALR) Assets - Slideshow
seekingalpha.com - July 19 at 6:08 AM |
 | Here's Why Quidel Corporation Is Rising Today
www.fool.com - July 18 at 1:17 PM |
| Quidel Corporation (NASDAQ:QDEL) Lifted to Buy at Canaccord Genuity
www.americanbankingnews.com - July 18 at 10:40 AM |
| Quidel Corporation (NASDAQ:QDEL) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - July 18 at 9:11 AM |
 | Mid-Afternoon Market Update: Peregrine Pharma Drops After Q4 Results; Quidel Shares Jump
feeds.benzinga.com - July 17 at 3:48 PM |
| Market Enthusiastic Ahead Of Earnings Season
www.rttnews.com - July 17 at 8:33 AM |
| Quidel announces definitive agreement to acquire Alere Triage Assets
seekingalpha.com - July 17 at 8:33 AM |
| Quidel Announces Definitive Agreement to Acquire Alere Triage® Assets
finance.yahoo.com - July 17 at 8:33 AM |
| BidaskClub Downgrades Quidel Corporation (NASDAQ:QDEL) to Buy
www.americanbankingnews.com - July 16 at 10:08 PM |
| Quidel to Hold Second Quarter 2017 Financial Results Conference Call on July 26, 2017
finance.yahoo.com - July 15 at 7:50 AM |
| Brokerages Anticipate Quidel Corporation (NASDAQ:QDEL) Will Post Quarterly Sales of $42.17 Million
www.americanbankingnews.com - July 13 at 10:00 AM |
| Zacks: Brokerages Expect Quidel Corporation (QDEL) to Announce -$0.17 Earnings Per Share
www.americanbankingnews.com - July 11 at 6:16 PM |
| Quidel Corporation (NASDAQ:QDEL) Upgraded by TheStreet to "B-"
www.americanbankingnews.com - July 11 at 11:54 AM |
| Quidel Corporation (NASDAQ:QDEL) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 7 at 8:11 AM |
| Quidel Corporation (QDEL) CEO Douglas C. Bryant Sells 36,000 Shares
www.americanbankingnews.com - June 30 at 10:30 PM |
| Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Instrument for Use with Sofia Respiratory Syncytial Virus (RSV) Assay
finance.yahoo.com - June 29 at 6:24 AM |
| Quidel’s Sofia® 2 Point-of-Care Immunoassay Analyzer Receives Multiple Awards from Good Design Australia®’s 2017 Good Design Awards®
finance.yahoo.com - June 23 at 9:22 AM |
| Brokerages Anticipate Quidel Corporation (QDEL) Will Post Quarterly Sales of $42.17 Million
www.americanbankingnews.com - June 17 at 8:46 AM |
| -$0.17 EPS Expected for Quidel Corporation (QDEL) This Quarter
www.americanbankingnews.com - June 15 at 6:28 PM |
| Oxford Immunotec Global PLC (OXFD) & Quidel Corporation (QDEL) Head to Head Contrast
www.americanbankingnews.com - June 13 at 8:16 PM |
| IDEXX Laboratories (IDXX) & Quidel Corporation (QDEL) Financial Comparison
www.americanbankingnews.com - June 13 at 4:49 PM |
| Quidel Corporation (QDEL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 12 at 8:48 AM |
| Quidel Receives the CE Mark for Its Thyretain® TBI Reporter BioAssay
finance.yahoo.com - June 8 at 12:23 AM |
| Reviewing Trinity Biotech plc (TRIB) and Quidel (QDEL)
www.americanbankingnews.com - June 5 at 4:10 PM |
| Insider Selling: Quidel Co. (QDEL) CEO Sells 12,000 Shares of Stock
www.americanbankingnews.com - May 31 at 10:28 PM |
| Quidel Co. (QDEL) CEO Sells $899,280.00 in Stock
www.americanbankingnews.com - May 31 at 10:26 PM |
| Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Immunoassay Analyzer for Use with Sofia Influenza A+B Assay
finance.yahoo.com - May 30 at 7:05 PM |
| FDA OKs Quidel's flu test for Sofia analyzer; shares up 2%
seekingalpha.com - May 30 at 4:17 PM |
| Quidel Receives PMDA Approval for Its Point-of-Care Sofia® Influenza A+B Assay
finance.yahoo.com - May 25 at 5:47 AM |
| ETFs with exposure to Quidel Corp. : May 18, 2017
finance.yahoo.com - May 19 at 12:16 PM |
| Quidel's (QDEL) "Hold" Rating Reiterated at Canaccord Genuity
www.americanbankingnews.com - May 19 at 10:52 AM |
Quidel Corporation (QDEL) Chart for Sunday, August, 20, 2017
